Table 1 Baseline characteristics of patients at the time of AF therapy initiation (in the NIN group) or enrollment (in the no-antifibrotic group)
Characteristic | N | Overall, N = 6111 | NIN, N = 4301 | NAF, N = 1811 | p-value2 |
|---|---|---|---|---|---|
Men | 611 | 438 (72%) | 324 (75%) | 114 (63%) | 0.002 |
Age at therapy initiation (years) | 611 | 71 (8) | 70 (8) | 73 (8) | 0.001 |
Length of follow-up (months) | 611 | 17 (6–34) | 20 (9–37) | 9 (3–26) | < 0.001 |
Duration of symptoms (months) | 601 | 601 / 12 (3; 60) | 423 / 12 (3; 60) | 178 / 12 (2; 60) | 0.007 |
Smoking status | 611 | 0.037 | |||
Non-smokers | 272 (45%) | 202 (47%) | 70 (39%) | ||
Ex-smokers | 319 (52%) | 218 (51%) | 101 (56%) | ||
Smokers | 20 (3.3%) | 10 (2.3%) | 10 (5.5%) | ||
Pharmacological treatment | 611 | ||||
Pirfenidone | 0 (0%) | 0 (0%) | 0 (NA%) | ||
Nintedanib | 430 (70%) | 430 (100%) | 0 (NA%) | ||
FVC (L) | 559 | 2.76 (0.81) | 2.75 (0.74) | 2.78 (0.93) | 0.658 |
FVC (%) | 556 | 81 (18) | 78 (14) | 88 (23) | < 0.001 |
FEV1 (%) | 557 | 86 (24) | 84 (15) | 89 (36) | 0.075 |
DLco (%) | 544 | 49 (15) | 49 (14) | 50 (19) | 0.375 |
GAP index | 551 | 0.002 | |||
I | 286 (52%) | 185 (49%) | 101 (59%) | ||
II | 223 (40%) | 171 (45%) | 52 (30%) | ||
III | 42 (7.6%) | 23 (6.1%) | 19 (11%) | ||
CPI | 533 | 46 (37–54) | 47 (40–55) | 41 (32–50) | < 0.001 |
CPI | 533 | < 0.001 | |||
≤ 41 | 198 (37%) | 115 (31%) | 83 (52%) | ||
> 41 | 335 (63%) | 258 (69%) | 77 (48%) |